On 29 June 2021, the Federal Court of Appeal set aside the Federal Court's decision dismissing Alexion's application for judicial review and remitted the matter of whether Alexion's Soliris (eculizumab) was sold at an excessive price back to the Patented Medicine Prices Review Board (PMPRB) for redetermination (for further information, please see "FCA remits pricing decision on ALEXION'S SOLIRIS to PMPRB").

On 1 April 2022, the PMPRB announced that it will hold a public rehearing of the matter. The rehearing is scheduled to be held on 20 June 2022.

For further information on this topic please contact Katie Lee at Smart & Biggar by telephone (+1 416 593 5514) or email ([email protected]). The Smart & Biggar website can be accessed at www.smartbiggar.ca.